Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215094494> ?p ?o ?g. }
- W3215094494 abstract "Targeted therapies represent attractive combination partners with immune checkpoint blockade (ICB) to increase the population of patients who benefit or to interdict the emergence of resistance. We demonstrate that targeting WEE1 up-regulates immune signaling through the double-stranded RNA (dsRNA) viral defense pathway with subsequent responsiveness to immune checkpoint blockade even in cGAS/STING-deficient tumors, which is a typical phenotype across multiple cancer types. WEE1 inhibition increases endogenous retroviral elements (ERVs) expression by relieving SETDB1/H3K9me3 repression through down-regulating FOXM1. ERVs trigger dsRNA stress and interferon response, increasing recruitment of anti-tumor T cells with concurrent PD-L1 elevation in multiple tumor models. Furthermore, combining WEE1 inhibition and PD-L1 blockade induced striking tumor regression in a CD8+ T cell–dependent manner. A WEE1 inhibition–induced viral defense signature provides a potentially informative biomarker for patient selection for combination therapy with WEE1 and ICB. WEE1 inhibition stimulates anti-tumor immunity and enhances sensitivity to ICB, providing a rationale for the combination of WEE1 inhibitors and ICB in clinical trials." @default.
- W3215094494 created "2021-12-06" @default.
- W3215094494 creator A5000213083 @default.
- W3215094494 creator A5001079874 @default.
- W3215094494 creator A5003360183 @default.
- W3215094494 creator A5005221518 @default.
- W3215094494 creator A5008366921 @default.
- W3215094494 creator A5009080782 @default.
- W3215094494 creator A5013167986 @default.
- W3215094494 creator A5015584107 @default.
- W3215094494 creator A5020581776 @default.
- W3215094494 creator A5022508447 @default.
- W3215094494 creator A5032931020 @default.
- W3215094494 creator A5034030001 @default.
- W3215094494 creator A5039787544 @default.
- W3215094494 creator A5045067652 @default.
- W3215094494 creator A5056078581 @default.
- W3215094494 creator A5057243097 @default.
- W3215094494 creator A5071623616 @default.
- W3215094494 creator A5073228982 @default.
- W3215094494 creator A5083907893 @default.
- W3215094494 creator A5089818348 @default.
- W3215094494 creator A5090776157 @default.
- W3215094494 date "2021-11-26" @default.
- W3215094494 modified "2023-10-15" @default.
- W3215094494 title "WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway" @default.
- W3215094494 cites W1611944043 @default.
- W3215094494 cites W1793067559 @default.
- W3215094494 cites W1953890763 @default.
- W3215094494 cites W1970308473 @default.
- W3215094494 cites W1997069349 @default.
- W3215094494 cites W2019918282 @default.
- W3215094494 cites W2021341670 @default.
- W3215094494 cites W2035618305 @default.
- W3215094494 cites W2036897871 @default.
- W3215094494 cites W2070050178 @default.
- W3215094494 cites W2082632613 @default.
- W3215094494 cites W2093442957 @default.
- W3215094494 cites W2104885590 @default.
- W3215094494 cites W2107458751 @default.
- W3215094494 cites W2124985265 @default.
- W3215094494 cites W2129785061 @default.
- W3215094494 cites W2147622445 @default.
- W3215094494 cites W2152239989 @default.
- W3215094494 cites W2158789637 @default.
- W3215094494 cites W2159707944 @default.
- W3215094494 cites W2169456326 @default.
- W3215094494 cites W2292383635 @default.
- W3215094494 cites W2338782656 @default.
- W3215094494 cites W2345356016 @default.
- W3215094494 cites W2468444838 @default.
- W3215094494 cites W2470708296 @default.
- W3215094494 cites W2502908858 @default.
- W3215094494 cites W2509217584 @default.
- W3215094494 cites W2528138045 @default.
- W3215094494 cites W2544405043 @default.
- W3215094494 cites W2547988452 @default.
- W3215094494 cites W2588362428 @default.
- W3215094494 cites W2613990808 @default.
- W3215094494 cites W2620099337 @default.
- W3215094494 cites W2724118546 @default.
- W3215094494 cites W2791440239 @default.
- W3215094494 cites W2799739256 @default.
- W3215094494 cites W2809237949 @default.
- W3215094494 cites W2883220169 @default.
- W3215094494 cites W2890261294 @default.
- W3215094494 cites W2890410994 @default.
- W3215094494 cites W2904099327 @default.
- W3215094494 cites W2906160139 @default.
- W3215094494 cites W2911940503 @default.
- W3215094494 cites W2934953754 @default.
- W3215094494 cites W2949415937 @default.
- W3215094494 cites W2968502728 @default.
- W3215094494 cites W2988196851 @default.
- W3215094494 cites W2995171541 @default.
- W3215094494 cites W3001160691 @default.
- W3215094494 cites W3030876661 @default.
- W3215094494 cites W3093933677 @default.
- W3215094494 cites W3119554079 @default.
- W3215094494 cites W3122624214 @default.
- W3215094494 cites W3126592381 @default.
- W3215094494 cites W634312238 @default.
- W3215094494 doi "https://doi.org/10.1084/jem.20210789" @default.
- W3215094494 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8628262" @default.
- W3215094494 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34825915" @default.
- W3215094494 hasPublicationYear "2021" @default.
- W3215094494 type Work @default.
- W3215094494 sameAs 3215094494 @default.
- W3215094494 citedByCount "16" @default.
- W3215094494 countsByYear W32150944942022 @default.
- W3215094494 countsByYear W32150944942023 @default.
- W3215094494 crossrefType "journal-article" @default.
- W3215094494 hasAuthorship W3215094494A5000213083 @default.
- W3215094494 hasAuthorship W3215094494A5001079874 @default.
- W3215094494 hasAuthorship W3215094494A5003360183 @default.
- W3215094494 hasAuthorship W3215094494A5005221518 @default.
- W3215094494 hasAuthorship W3215094494A5008366921 @default.
- W3215094494 hasAuthorship W3215094494A5009080782 @default.
- W3215094494 hasAuthorship W3215094494A5013167986 @default.
- W3215094494 hasAuthorship W3215094494A5015584107 @default.